NUCIEN PHARMA plans to acquire the target asset group held by Future Medicine for no more than 480 million yuan to enrich the company's product pipeline

According to the news from Zhitong Finance APP, NUCIEN PHARMA (688189.SH) announced that the company has signed a "Letter of Intent for Acquisition" with Tibet Future Biopharmaceutical Co., Ltd., Xuchang Future Pharmaceutical Co., Ltd., and Hefei Future Drug Development Co., Ltd. (collectively referred to as "Future Pharmaceuticals"). The company intends to acquire the target asset group held by Future Pharmaceuticals for cash not exceeding 480 million yuan, including the listed target products "Multi-trace Element Injection (I)", "Multi-trace Element Injection (II)", and the research and development target product "Multi-trace Element Injection (III)", as well as the complete ownership and intellectual property rights of related research and development and production technical materials, trademarks, patents, customer information (market channels), approvals, and other assets ("this transaction").

According to preliminary research and calculations, this transaction is expected to constitute a significant asset restructuring situation as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies." The transaction is intended to be a cash acquisition, does not involve the issuance of shares by the company, does not constitute a related party transaction, and will not lead to a change in the company's control.

It is reported that the acquisition of the asset group related to Future Pharmaceuticals' Multi-trace Element Injections (I, II, III) will further enrich the company's product pipeline, improve the company's product matrix for "health management for all ages," and optimize the company's product layout for "anti-infection - chronic disease - nutritional support," aligning with the company's "big health" development strategy. The Multi-trace Element Injections (I, II) from Future Pharmaceuticals have already formed a scale of sales in the market, which can bring certain revenue and profit growth points to the company in the short term.

In addition, the asset group purchased in this transaction includes its established and mature nationwide sales channels and academic promotion system. The company will leverage its comprehensive sales network and academic promotion system to explore new sales channels for its products and significantly promote the market access and coverage of the company's pediatric anti-influenza drugs